Last reviewed · How we verify
Reopro (ABCIXIMAB)
Reopro (abciximab) is a medication originally developed by Centocor Inc, currently owned by the same company. It targets the integrin alpha-IIb/beta-3, a protein involved in platelet aggregation. Reopro is used to treat patients undergoing percutaneous coronary intervention, and it was FDA-approved in 1993. The commercial status of Reopro is patented, and it is not yet available as a generic medication. Key safety considerations include bleeding risks and allergic reactions.
At a glance
| Generic name | ABCIXIMAB |
|---|---|
| Sponsor | Johnson & Johnson |
| Target | Integrin alpha-IIb/beta-3 |
| Modality | Monoclonal antibody |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1993 |
Approved indications
- Percutaneous coronary intervention
Common side effects
Key clinical trials
- Deferred Stenting in Patients With Anterior Wall STEMI (NA)
- Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients (PHASE2)
- ClearWay Rx Readmission Registry
- Aspirin Resistance and Percutaneous Coronary Intervention (PCI) (PHASE2)
- ReoPro and Retavase to Treat Acute Stroke (PHASE2)
- Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients (PHASE2)
- European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial (PHASE3)
- Stroke Prevention With Abciximab in Carotid Endarterectomy (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reopro CI brief — competitive landscape report
- Reopro updates RSS · CI watch RSS
- Johnson & Johnson portfolio CI